Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ramipril -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ramipril -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 2 mg - capsule - excipient ingredients: lactose monohydrate; povidone; sodium stearylfumarate; maize starch; titanium dioxide; purified water; iron oxide yellow; erythrosine; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 1 mg - capsule - excipient ingredients: maize starch; sodium stearylfumarate; povidone; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 0.5 mg - capsule - excipient ingredients: povidone; sodium stearylfumarate; maize starch; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - oseltamivir phosphate, quantity: 98.524 mg - capsule, hard - excipient ingredients: povidone; sodium stearylfumarate; pregelatinised maize starch; purified talc; croscarmellose sodium; ethanol absolute; titanium dioxide; purified water; iron oxide yellow; gelatin; iron oxide black - oseltamivir is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - oseltamivir phosphate, quantity: 59.114 mg - capsule, hard - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; sodium stearylfumarate; povidone; purified talc; ethanol absolute; titanium dioxide; purified water; gelatin; iron oxide black - oseltamivir is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - oseltamivir phosphate, quantity: 39.41 mg - capsule, hard - excipient ingredients: sodium stearylfumarate; ethanol absolute; pregelatinised maize starch; croscarmellose sodium; povidone; purified talc; titanium dioxide; purified water; iron oxide yellow; gelatin - oseltamivir is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: hyprolose; iron oxide yellow; magnesium stearate; magnesium carbonate hydrate; polysorbate 80; microcrystalline cellulose; mannitol; iron oxide red; purified water; crospovidone; titanium dioxide; hypromellose; polyacrylate dispersion (30 per cent); purified talc; glyceryl monostearate; triethyl citrate; aspartame; methacrylic acid - ethyl acrylate copolymer (1:1); citric acid; macrogol 6000; flavour; xylitol; calcium hydrogen phosphate - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: macrogol 6000; magnesium carbonate hydrate; purified water; hypromellose; polyacrylate dispersion (30 per cent); microcrystalline cellulose; triethyl citrate; iron oxide red; polysorbate 80; glyceryl monostearate; citric acid; titanium dioxide; purified talc; hyprolose; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); crospovidone; magnesium stearate; mannitol; aspartame; xylitol; calcium hydrogen phosphate; flavour - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.